Anti-angiogenic alternatives to VEGF blockade

被引:28
|
作者
Khan, Kabir A. [1 ]
Bicknell, Roy [1 ]
机构
[1] Univ Birmingham, Coll Med & Dent Sci, Sch Cardiovasc Res, Angiogenesis Lab,Inst Biomed Res, Birmingham, W Midlands, England
关键词
Angiogenesis; Anti-angiogenesis; Cancer; Tumour; Therapy; ANTI-ALPHA-5-BETA-1 INTEGRIN ANTIBODY; ENDOTHELIAL-CELL PROLIFERATION; FIBROBLAST GROWTH-FACTORS; INHIBITS TUMOR-GROWTH; MONOCLONAL-ANTIBODY; ANTIANGIOGENIC THERAPY; UP-REGULATION; ENDOGLIN ANTIBODY; ANGIOPOIETIN; OPEN-LABEL;
D O I
10.1007/s10585-015-9769-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy.
引用
收藏
页码:197 / 210
页数:14
相关论文
共 50 条
  • [1] Anti-angiogenic alternatives to VEGF blockade
    Kabir A. Khan
    Roy Bicknell
    Clinical & Experimental Metastasis, 2016, 33 : 197 - 210
  • [2] ANTI-ANGIOGENIC ISOFORMS OF VEGF - A KEY TO ANTI-ANGIOGENIC THERAPY
    Bates, D. O.
    Harper, S. J.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3207 - 3208
  • [3] Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects
    Joly, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 35 - 35
  • [4] Development of an anti-angiogenic vaccine targeting VEGF
    Wentink, Madelon Q.
    Griffioen, Arjan W.
    Timmerman, Peter
    de Gruijl, Tanja D.
    Verheul, Henk M. W.
    ANGIOGENESIS, 2014, 17 (03) : 772 - 773
  • [5] The anti-angiogenic isoforms of VEGF in health and disease
    Qiu, Yan
    Hoareau-Aveilla, Coralie
    Oltean, Sebastian
    Harper, Steven J.
    Bates, David O.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2009, 37 : 1207 - 1213
  • [6] Is VEGF a predictive biomarker to anti-angiogenic therapy?
    Otrock, Zaher K.
    Hatoum, Hassan A.
    Musallam, Khaled M.
    Awada, Ahmad H.
    Shamseddine, Ali I.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) : 103 - 111
  • [7] VEGF-A splicing: the key to anti-angiogenic therapeutics?
    Harper, Steven J.
    Bates, David O.
    NATURE REVIEWS CANCER, 2008, 8 (11) : 880 - 887
  • [8] VEGF-A splicing: the key to anti-angiogenic therapeutics?
    Steven J. Harper
    David O. Bates
    Nature Reviews Cancer, 2008, 8 : 880 - 887
  • [9] Unusual anti-angiogenic effect of combined hormonal blockade
    Tisman, G
    JOURNAL OF UROLOGY, 2002, 168 (04): : 1495 - 1495
  • [10] PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
    Kim, Sun Hwa
    Jeong, Ji Hoon
    Lee, Soo Hyun
    Kim, Sung Wan
    Park, Tae Gwan
    JOURNAL OF CONTROLLED RELEASE, 2006, 116 (02) : 123 - 129